Aerovate Therapeutics Inc (AVTE)

Nov 4, 2024, 6:07 PM EST - 2 months ago

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE

Nov 1, 2024, 12:02 PM EDT - 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

PFIE

Jul 8, 2024, 8:00 AM EDT - 6 months ago

Aerovate Therapeutics to Explore Strategic Alternatives

Jun 21, 2024, 2:00 PM EDT - 7 months ago

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

Jun 20, 2024, 1:22 PM EDT - 7 months ago

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Jun 17, 2024, 8:32 AM EDT - 7 months ago

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Jun 11, 2024, 1:19 PM EDT - 7 months ago

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

May 21, 2024, 4:15 PM EDT - 8 months ago

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

May 13, 2024, 4:30 PM EDT - 8 months ago

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Mar 27, 2024, 9:20 AM EDT - 10 months ago

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Mar 25, 2024, 4:10 PM EDT - 10 months ago

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Mar 6, 2024, 8:00 AM EST - 11 months ago

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Nov 20, 2023, 4:45 PM EST - 1 year ago

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Nov 13, 2023, 8:00 AM EST - 1 year ago

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

Jul 11, 2023, 5:00 PM EDT - 1 year ago

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

Jun 28, 2023, 8:00 AM EDT - 1 year ago

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

May 22, 2023, 1:15 PM EDT - 1 year ago

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

May 15, 2023, 4:05 PM EDT - 1 year ago

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Apr 12, 2023, 8:45 AM EDT - 1 year ago

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

Mar 29, 2023, 4:50 PM EDT - 1 year ago

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

Mar 2, 2023, 8:00 AM EST - 2 years ago

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

Jan 29, 2023, 7:12 AM EST - 2 years ago

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Jan 23, 2023, 8:00 AM EST - 2 years ago

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

Nov 17, 2022, 7:45 AM EST - 2 years ago

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Nov 14, 2022, 7:45 AM EST - 2 years ago

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

Oct 18, 2022, 8:00 AM EDT - 2 years ago

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

Aug 15, 2022, 7:50 AM EDT - 2 years ago

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

May 16, 2022, 5:15 PM EDT - 2 years ago

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

May 16, 2022, 8:00 AM EDT - 2 years ago

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

Mar 30, 2022, 4:45 PM EDT - 3 years ago

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Dec 15, 2021, 8:00 AM EST - 3 years ago

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Nov 15, 2021, 8:00 AM EST - 3 years ago

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

Sep 17, 2021, 8:00 AM EDT - 3 years ago

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

Aug 16, 2021, 8:00 AM EDT - 3 years ago

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

Jul 2, 2021, 4:01 PM EDT - 3 years ago

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jun 30, 2021, 3:37 PM EDT - 3 years ago

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Jun 29, 2021, 10:59 PM EDT - 3 years ago

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

Jun 28, 2021, 8:00 PM EDT - 3 years ago

Aerovate Therapeutics Readies $100 Million IPO Effort